NCT06045364

Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: Jie Chen · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.

Detailed description

This study is a prospective, double-blind, randomized controlled trial. Patients who meet the criteria of our center and need to undergo ERCP lesion resection will be included and randomly divided into groups. After receiving Glycopyrrolate (experimental group) and Anisodamine (control group), duodenal peristalsis, biliary and pancreatic treatment time and postoperative nausea and vomiting will be observed during therapeutic ERCP. The inhibitory effect of Glycopyrrolate on postoperative nausea and vomiting of ERCP will be analyzed statistically. Main outcome measure: incidence of nausea and vomiting after ERCP Secondary outcome measures: mean duodenal contractions per minute, duodenal spasm frequency and score, ERCP operation time, occurrence of other side effects of medication, remedial medication, and incidence of adverse events

Conditions

• Nausea and Vomiting

Interventions

Type	Name	Description
DRUG	Glycopyrrolate	During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
DRUG	Anisodamine	During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.

Timeline

• Start date: 2023-10-01
• Primary completion: 2024-07-20
• Completion: 2024-07-31
• First posted: 2023-09-21
• Last updated: 2024-09-05

Locations

1 site across 1 country: China